Back
EA Forum - What 1Day Sooner Would Do with Your Marginal Dollar: Hepatitis C
blogCredibility Rating
3/5
Good(3)Good quality. Reputable source with community review or editorial standards, but less rigorous than peer-reviewed venues.
Rating inherited from publication venue: EA Forum
This EA Forum post is a fundraising pitch from 1Day Sooner; it is tangential to AI safety but illustrates high-leverage policy advocacy and funding redirection strategies that may interest those studying coordination and cause prioritization within EA.
Forum Post Details
Karma
13
Comments
0
Forum
eaforum
Forum Tags
Global health & developmentPolicy1Day SoonerGiving Season (2025)Global catastrophic riskMarginal Funding Week (2025)
Metadata
Importance: 22/100blog postanalysis
Summary
1Day Sooner seeks $50-200K to hire staff for hepatitis C vaccine policy advocacy, targeting a strategic opportunity to redirect NIH funding from HIV vaccines toward hepatitis C research. Their plan centers on hosting a 2026 NIH workshop and follow-up activities aimed at catalyzing over $10M in new funding for an underfunded field. The organization argues this represents exceptional leverage, potentially increasing current hepatitis C vaccine funding by more than 50%.
Key Points
- •1Day Sooner requests $50-200K to fund staff dedicated to hepatitis C vaccine policy advocacy and NIH funding redirection efforts.
- •The opportunity arises from HIV vaccine funding becoming less impactful following lenacapavir approval, freeing resources for reallocation.
- •A planned 2026 NIH workshop on hepatitis C vaccines is the centerpiece strategy, with follow-up advocacy to secure $10M+ in funding.
- •Hepatitis C vaccine research is significantly underfunded; the proposed catalyzed funding could represent over 50% of current field investment.
- •1Day Sooner frames this as a high-leverage philanthropic opportunity with strong cost-effectiveness given the small input and large potential output.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| 1Day Sooner | Organization | 60.0 |
Cached Content Preview
HTTP 200Fetched Mar 15, 20264 KB
What 1Day Sooner would do with your marginal dollar: Hepatitis C Vaccine Advocacy — EA Forum
This website requires javascript to properly function. Consider activating javascript to get access to all site functionality. What 1Day Sooner would do with your marginal dollar: Hepatitis C Vaccine Advocacy
by 1daysooner , Josh Morrison Nov 19 2025 2 min read 0 13
Global health & development Policy 1Day Sooner Giving Season (2025) Global catastrophic risk Marginal Funding Week (2025) Frontpage 1Day Sooner advocates on behalf of people who join medical studies for altruistic reasons. We focus particularly on “challenge studies,” where participants are exposed to pathogens to develop vaccines and learn about infectious disease. We work at three levels: trials, technologies, and policies. Our best analysis of our knowable causal impact through summer of 2024 can be found here . We believe we have a strong opportunity to generate millions of dollars in funding for hepatitis C vaccine development for $50-200K.
This year, we expanded our trials work by launching our “ Cooperative Participant Organization ,” which provides support to trial teams working on high-value infectious disease research. This has expanded our trial support work from our previous focus on hepatitis C challenge studies to cover enteric, parasitic, and other hepatic trials.
But expanding our trials work has opened up a gap in advancing hepatitis C vaccine technologies, since the team that previously covered both trials and hepatitis C vaccines now have a wider range of responsibilities. We have an opportunity that we think could lead to >$10M in funding from the NIH for hepatitis C vaccine development (including hepatitis C challenge studies), but we currently do not have the staffing to adequately pursue it. To make this project sustainable, we need at least $50K to hire a contractor and ideally $200K to hire a staffer to work full-time on advancing the hepatitis C vaccine field.
The opportunity is to move NIH funding currently devoted to supporting HIV vaccines to support hepatitis C vaccines (including support for challenge studies). Besides COVID, HIV vaccines have received the most funding of any disease, but they have proven extremely difficult to develop. The recent approval of the highly effective prophylactic lenacapavir significantly reduces the counterfactual value of an HIV vaccine. At the same time, the coinfection of much of the HIV patient population with hepatitis C creates an opening to redirect some funds to the far less well-funded area of hepatitis C vaccine development.
To advance this goal, last year the NIH had planned to conduct a workshop on hepatitis C challenge studies, to be attended by key HIV stakeholders. Due to the change in administration and reductions in force of NIH staff, this workshop did not occur. After our discussions with the NIH team who had planned that workshop, we think hosting it in 2026 would accomplish its original purpose
... (truncated, 4 KB total)Resource ID:
eefc00a67d56bb7b | Stable ID: MzFlZmQ2Yj